The use of infliximab in cutaneous sarcoidosis.

Jon H. Meyerle, Andrew Shorr

Research output: Contribution to journalArticle

Abstract

Infliximab, a chimeric (humanized mouse) monoclonal antibody which specifically inhibits TNF-alpha, has recently shown efficacy in the treatment of refractory sarcoidosis. The manifestations of sarcoidosis are diverse; however, the long-term effects on the lungs are often the most life-threatening. We describe a patient with sarcoidosis who experienced the complete resolution of her cutaneous disease and stabilization of her pulmonary symptoms after initiation of infliximab.

Original languageEnglish (US)
Pages (from-to)413-414
Number of pages2
JournalJournal of drugs in dermatology : JDD
Volume2
Issue number4
StatePublished - Aug 2003

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'The use of infliximab in cutaneous sarcoidosis.'. Together they form a unique fingerprint.

  • Cite this